long-term efficacy of treatment with lamivudine in hbeag-negative patients with decompensated cirrhosis due to chronic hepatitis b
نویسندگان
چکیده
background: the prognosis of patients with decompensated cirrhosis due to hepatitis b is very poor. it has been shown that lamivudine can improve liver function and delay the need for liver transplantation in hbeag-positive patients with decompensated cirrhosis. however, information regarding long-term use of lamivudine in hbeag-negative patients with cirrhosis is limited. the primary objective of this study was to evaluate the long-term efficacy of lamivudine in hbeag-negative/hbeab-positive patients with decompensated cirrhosis. materials and methods: 54 consecutive hbeag-negative/hbeab-positive patients with decompensated cirrhosis were enrolled into this study. all patients were treated with 100 mg lamivudine per day. significant clinical improvement was defined as a decrease of at least 2 points in child-pugh-turcotte (cpt) score. repeated-measure one-way analysis of variance was used to evaluate the effect of time interval of lamivudine treatment on different variables. kaplan-meier survival analysis and mantel-cox test were used to further analyze the data. results: the meanâ±sd age of patients was 50.6â±13.2 years. there were 40 male and 14 female patients. the median follow-up was 29 (range: 6-64) months. cpt score, meld score and blood chemistries changed significantly after 6 months of therapy. the favorable changes were continued up to 2 years. in spite of worsening after 3 years, within subject effects measured by repeated-measure anova, were significant for patients who have received lamivudine for 4 years or more. conclusions: long-term lamivudine therapy improves liver function in hbeag-negative/hbeab-positive patients with decompensated cirrhosis.
منابع مشابه
Association between KIR Genes and Efficacy of Treatment of HBeAg-Positive Chronic Hepatitis B Patients with Entecavir
Background: Entecavir (ETV) is commonly used to treat chronic hepatitis B (CHB) in China. However, certain percentages of e-Antigen (HBeAg) positive CHB patients do not respond to ETV therapy. Objective: To investigate whether the killer immunoglobulin-like receptor (KIR) genes were associated with seroconversion in HBeAg positive CHB responder patients treated with ETV. Methods: Polymerase cha...
متن کاملEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
BACKGROUND Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. METHODS In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of en...
متن کاملClinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study
The optimal duration of oral nucleos(t)ide analogue therapy for HBeAg negative chronic hepatitis B (CHB) has not been defined. The aim of this study was to investigate the clinical efficacy of 24-months course of lamivudine therapy in patients with HBeAg negative CHB in Korea. A total of 50 Korean patients with HBeAg negative CHB were prospectively enrolled. The patients received 100 mg/day of ...
متن کاملRescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
BACKGROUND/AIMS Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV. METHODS In total, 128 patients with a decompensated state and lamivudine-resistant HBV were tre...
متن کاملPredictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis B.
INTRODUCTION Although pegylated interferons (pegIFNs) alpha-2a and alpha-2b have been used in chronic hepatitis B (CHB) treatment for many years, there are few studies concerning predictors of sustained virologic response (SVR) to pegIFN therapy. In this study, we aimed to investigate the predictors of response to pegIFN treatment in cases with HBeAg-negative CHB infection. METHODOLOGY Sevent...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
گوارشجلد ۱۱، شماره ۳، صفحات ۱۹۱-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023